STOCK TITAN

Atossa Therapeutics (ATOS) Net Income by Year

ATOS NASDAQ

Atossa Therapeutics, Inc. reported a net loss of $34.8M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a $34.7M net loss. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Atossa Therapeutics, Inc. has filed alongside them.

FY2025 annual
Net Income -$34.8M
YoY n/m
5Y CAGR n/m
10Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

ATOS Net Income by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
Net Income-$34.7M-$34.8Mn/m-$25.5Mn/m-$30.1Mn/m-$27.0Mn/m-$20.6Mn/m-$17.8Mn/m-$17.2Mn/m-$11.4Mn/m-$8.1Mn/m-$6.4Mn/m-$15.8Mn/m-$14.7Mn/m-$10.8Mn/m-$5.1Mn/m-$3.4M

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

ATOS Net Income by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Net Income-$5.6Mn/m-$8.5Mn/m-$9.6Mn/m-$10.9Mn/m-$8.7Mn/m-$8.4Mn/m-$6.7Mn/m-$6.3Mn/m-$7.2Mn/m-$6.0Mn/m-$5.9Mn/m-$7.8Mn/m

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Atossa Therapeutics, Inc. financials

Frequently Asked Questions

Atossa Therapeutics, Inc. reported a net loss of $34.8M in fiscal year 2025.

Atossa Therapeutics, Inc. (ATOS) reported a $25.5M net loss in fiscal year 2024 and a $34.8M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Atossa Therapeutics, Inc. (ATOS) reported a $34.7M net loss over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, Atossa Therapeutics, Inc. (ATOS) net income went from -$3.4M in fiscal year 2011 to -$34.8M in fiscal year 2025.

Atossa Therapeutics, Inc. (ATOS) reported -$5.6M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Atossa Therapeutics, Inc. (ATOS) reported on that line in every period on record.